RPG Life Sciences Ltd.
Snapshot View

509.30 -0.75 ▼-0.2%

30 July 2021, 04:00:00 P.M.
Volume: 27,286

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.rpglifesciences.com
Financial Indicators
Market Cap 841.42 Cr.
Earnings per share (EPS) 26.92 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 18.90 Trailing Twelve Months Ending 2021-06
Industry PE 35.15 Trailing Twelve Months Ending 2021-06
Book Value / Share 139.08 Trailing Twelve Months Ending 2021-06
Price to Book Value 3.66 Calculated using Price: 508.75
Dividend Yield 1.42 Period Ending 2020-03
No. of Shares Subscribed 1.65 Cr. 16,539,015 Shares
FaceValue 8
Company Profile

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.

Achievements:

  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.15%
1 Week
+10.93%
1 Month
+13.03%
3 Month
+5.80%
6 Month
+26.42%
1 Year
+60.84%
2 Year
+146.28%
5 Year
+31.99%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.14 5.87 52.87 0.80 8.98 14.98 8.91 6.86 17.21
Return on Capital Employed (%) 6.73 5.99 48.37 2.50 8.97 15.58 12.52 9.81 20.35
Return on Assets (%) 0.44 2.21 25.50 0.47 5.34 9.15 5.17 4.07 11.25

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 74 76 126 125 134 147 155 161 177
Non Curr. Liab. 42 22 7 20 22 11 8 10 9
Curr. Liab. 73 112 77 67 67 79 121 78 83
Minority Int.
Equity & Liab. 189 210 209 212 223 236 284 248 268
Non Curr. Assets 120 111 112 126 136 140 141 151 142
Curr. Assets 69 99 97 86 87 96 143 97 126
Misc. Exp. not W/O
Total Assets 189 210 209 212 223 236 284 248 268

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 193 222 236 242 279 294 344 330 376
Other Income 1 2 3 7 2 10 2 1 1
Total Income 194 224 238 249 281 303 346 331 377
Total Expenditure -175 -206 -224 -234 -257 -265 -307 -296 -316
PBIDT 19 18 14 15 24 38 39 35 61
Interest -7 -7 -3 -3 -2 -4 -5 -5 -3
Depreciation -10 -10 -11 -11 -10 -11 -14 -15 -16
Taxation -1 4 -12 -2 -7 -4 -7
Exceptional Items 64 -5
PAT 1 4 53 1 12 21 13 11 29

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 16 12 -6 -2 33 7 15 46 50
Cash Fr. Inv. -8 -12 59 -10 -15 -30 -16 -19 -11
Cash Fr. Finan. -8 0 -54 12 -18 23 0 -27 -39
Net Change 0 0 0 0 1 -1 0 0
Cash & Cash Eqvt 0 0 0 0 0 1 0 0 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07
Public 27.93 27.93 27.93 27.93 27.93 27.93 27.93 27.93 27.93
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations 2015 please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter ended June 30 2021.

Kindly take this information on record.
Wed, 28 Jul 2021
Unaudited Financial Result For The Quarter Ended June 30 2021
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Unaudited Financial Results for the quarter ended June 30 2021 which were approved by the Board of Directors of the Company at its meeting held on July 28 2021 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.

Kindly take the above on your record.
Wed, 28 Jul 2021
Board Meeting Outcome for Outcome Of Board Meeting Held On July 28 2021
In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company has at its meeting held on Wednesday July 28 2021 inter alia considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30 2021 along with Limited Review Report of the Statutory Auditors thereon.

The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.

Kindly take the same on your record.

Technical Scans View Details

Fri, 30 Jul 2021
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
ATR Increasing for 3 Days ATR Increasing for 3 Days
Stochastic %K Crossing %D from Above Stochastic %K Crossing %D from Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%